Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

FAK inhibitor

DRUG CLASS:

FAK inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

KRAS wild-type	Ovarian Cancer	KRAS wild-type	Ovarian Cancer	avutometinib + defactinib Sensitive: B - Late Trials avutometinib + defactinib Sensitive : B	avutometinib + defactinib Sensitive: B - Late Trials avutometinib + defactinib Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	IN10018 Sensitive: B - Late Trials IN10018 Sensitive : B	IN10018 Sensitive: B - Late Trials IN10018 Sensitive : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ALK positive	Mesothelioma	ALK positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3